Henlius Announces Positive Phase I/II Results For Ophthalmic Bevacizumab Biosimilar

HLX04-O Could Be One Of The First Bevacizumab Products Formally Indicated For Ophthalmology

 
• By Chloe Kent

Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.

Older woman undergoes eye test
Bevacizumab is usually used off-label to treat ocular conditions • Source: Shutterstock

More from Products

More from Generics Bulletin